News for Osmotica Pharmaceuticals plc (OSMT)

EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial...

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA...

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5...

Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. Click here for more on RVLP.

Read Analyzing Bioxytran (OTCMKTS:BIXT) and RVL Pharmaceuticals (NASDAQ:RVLP) at ETF Daily News

Read Contrasting RVL Pharmaceuticals (RVLP) and Its Competitors at ETF Daily News

Read Research Analysts’ Upgrades for May 19th (AAVMY, AAWW, AIT, AMOT, AMRN, AMZN, ATO, BCH, BCS, BECN) at ETF Daily News

Read RVL Pharmaceuticals (NASDAQ:RVLP) Upgraded at Zacks Investment Research at ETF Daily News

Read Reviewing RVL Pharmaceuticals (RVLP) & Its Competitors at ETF Daily News

RVLP | Complete RVL Pharmaceuticals PLC stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

DUBLIN, July 29, 2021 /PRNewswire/ -- The

Shares of Adamas Pharmaceuticals Inc. (ADMS) have recovered 140% from their 52-week low of $1.90 recorded on Mar.18, 2020, and trade around $4.50. Given the strong GOCOVRI sales, improving Namzaric royalties, and the upcoming FDA decision, Adamas is a stock worth following.